ArticleEuropean radiology2026
Factors associated with early complete resolution after radiofrequency ablation for low-risk papillary thyroid microcarcinoma: a dual-center retrospective study.
Article in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectivesTo identify predictors of early complete ablation zone resolution (within 1 year) after radiofrequency ablation (RFA) for low-risk papillary thyroid microcarcinoma (PTMC). MATERIALS AND
methodsA retrospective dual-center study enrolled 225 patients with low-risk PTMC (2017-2022). Ablation zone volume was tracked during follow-up, with the specific time of complete resolution modeled using exponential decay functions. Multivariable Cox regression and restricted cubic spline (RCS) analyses identified independent predictors of resolution.
resultsCumulative complete resolution rates were 62.2% at 1 year and 98.7% at 2 years. Independent predictors of complete resolution within 1 year included normal thyroglobulin antibody (TgAb) levels (hazard ratio (HR): 2.64, 95% confidence Interval (CI): 1.38-5.07) and thyroid peroxidase antibody (TPOAb) levels (HR: 1.92, 95% CI: 1.34-2.75), nodule diameter ≤ 5 mm (HR: 1.53, 95% CI: 1.02-2.29), and absence of intratumoral vascularity (HR: 2.77, 95% CI: 1.83-4.21). Energy density showed an inverted U-shaped relationship with resolution probability within 1 year (p < 0.001 for non-linearity).
conclusionRFA achieves favorable long-term efficacy for low-risk PTMC, and complete resolution within 1 year is predictable by normal TgAb/TPOAb, smaller nodule size, absence of intratumoral vascularity, and moderate energy density. These findings may provide valuable insights for refining RFA techniques and the development of personalized follow-up. KEY POINTS: Question Predicting early complete resolution of low-risk PTMC after RFA is critical to mitigate concerns about treatment outcomes and optimize follow-up. Findings Normal TgAb/TPOAb, smaller nodule size, absence of intratumoral vascularity, and moderate energy density independently predict early complete ablation zone resolution within 1 year after RFA. Clinical relevance Identifying predictors of early resolution enables optimized RFA energy delivery and pretreatment decision-making. This provides doctors and patients with evidence-based guidance to refine ablation strategies and personalize management plans.
Indexed as
Identifiers
41792573What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.